Bristol-Myers Squibb is requesting the Northern District of Florida as the appropriate venue in the upcoming multidistrict litigation (MDL) for federal lawsuits alleging compulsive gambling side effects from the antipsychotic drug Abilify (generic: aripiprazole).
Free Confidential Lawsuit Evaluation: If you or a loved one experienced compulsive behaviors after taking Abilify, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
What’s the problem?
October 3, 2016 – Florida was originally requested as the site for the MDL by a couple who filed one of the dozens of lawsuits alleging that Bristol-Myers Squibb and Otsuka Pharmaceutical Co. failed to adequately warn consumers about the risk of pathological gambling from Abilify, according to Law360.
The defendants consented to the couple’s motion, stressing that Chief District Judge M. Casey Rodgers is already overseeing 2 Abilify lawsuits in the Northern District of Pensacola, and is consulting with state court judges handling related cases. All of the complaints allege that Bristol-Myers and Otsuka failed to adequately warn users about an increased risk of pathological gambling with Abilify.
In May, the U.S. Food & Drug Administration (FDA) issued a Drug Safety Communication stating that labels of Abilify and other similar antipsychotics would be updated to include new warnings regarding compulsive behaviors such as gambling, sexual behavior, shopping and eating. The label change followed the agency’s review of at least 184 adverse event reports which suggested a link between aripiprazole (the active ingredient in Abilify) and impulse control problems. All 184 cases occurred from Nov. 2002 to Jan. 2016, with the reports noting that pathological urges stopped once the drug was discontinued or the dosage reduced.
Since Abilify was first approved by the FDA in 2002, more than 24 million prescriptions have been written for the drug. By waiting nearly 14 years to include gambling warnings on its labeling, the defendants made significantly more revenue off Abilify in the U.S. than in Europe where such warnings have been in place for years, according to the lawsuits. Bristol-Myers reported that U.S. revenues from Abilify sales topped $417 million over 3 months in 2014, while worldwide revenues were $555 million over the same period.
Do I Have an Abilify Gambling Lawsuit?
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently accepting new compulsive gambling cases in all 50 states.
Free Case Evaluation: Again, if you or a loved one experienced financial loss, family problems or legal consequences as a result of compulsive gambling while taking Abilify, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.